Nucleosides clinical trials
How each study uses Nucleosides is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Nucleosides studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2001 (1)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
University of Minnesota (1) · Johannes Gutenberg University Mainz (1) · Bristol-Myers Squibb (1) · Third Affiliated Hospital, Sun Yat-Sen University (1)
Often tested with
Tested in the same studies.
Efavirenz (1) · Peginterferon alfa-2a (1) · Atazanavir (1) · Ritonavir (1) · Tenofovir (1) · Saquinavir (1) · Lopinavir (1) · Peginterferon alfa-2b (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Nucleosides.
- Dec 2026Peginterferon Treatment Study for Inactive Chronic Hepatitis B PatientsPhase 4 · Third Affiliated Hospital, Sun Yat-Sen University
Studies
Open first, then newest update. How each study uses Nucleosides is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Peginterferon Treatment Study for Inactive Chronic Hepatitis B PatientsRecruitingPhase 4Third Affiliated Hospital, Sun Yat-Sen UniversityNCT05182463Written as Nucleoside Analogs
- Cryptococcal Optimal ART Timing TrialCompletedPhase 4University of MinnesotaNCT01075152Written as nucleoside
- Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-AntigenCompletedPhase 2Johannes Gutenberg University MainzNCT01524679Written as Pegylated interferon alfa-2a plus nucleos(t)ide(s)
- Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIVCompletedPhase 3Bristol-Myers SquibbNCT00035932Written as Atazanavir + ritonavir + tenofovir + nucleoside
Given beside what is tested · 6 — Nucleosides is usual care or a partner of the new treatment
- Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV InfectionActive, not recruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06706310Written as Nucleoside (acid) analogs (NAs)
- A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis BCompletedPhase 2Hoffmann-La RocheNCT04225715Written as Nucleos(t)ide (NUC)
- A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Sciences Ireland UCNCT03982186Written as Nucleos(t)ide Analog (NA)
- A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically SuppressedCompletedPhase 1Janssen Sciences Ireland UCNCT03463369Written as Nucleos(t)ide Analogs (NA)
- A Study in Healthy Volunteers and Patients With Chronic Hepatitis BCompletedPhase 1Assembly BiosciencesNCT02908191Written as Nucleos(t)ide
- Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative ResectionStatus unknownPhase 4Jia FanNCT02281266Written as nucleoside analog (suggest to use entecavir)